Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Utah Medical Products Inc

UTMD

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $71.54 – $73.43
Volume 10,693
Market cap $206M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$206.03M
Price / earnings
19.65×
Price / book
1.69×
Price / sales
5.71×
EV / sales
3.28×
EV / EBITDA
9.36×

Profitability

Earnings per share
$3.68
Return on assets
8.42%
Return on equity
8.59%
Dividend yield
1.91%

Liquidity and leverage

Debt / equity
0×
Current ratio
48.62×
Quick ratio
44.27×
Cash ratio
42.28×

Cash flow

Price / cash flow
17.39×
Price / free cash flow
18×
Free cash flow
$11.45M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for UTMD, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$8.53M$8.72M$9.05M$9.81M$9.95M$9.71M$9.16M$10.01M
Cost of revenue$3.77M$3.44M$3.78M$4.21M$4.36M$4.17M$3.84M$4.2M
Gross profit$4.76M$5.28M$5.26M$5.6M$5.6M$5.54M$5.32M$5.8M
Selling, general and administrative$1.96M$2.56M$2.61M$2.83M$2.26M$2.23M$2.27M$2.29M
Research and development$154K$154K$212K$167K$135K$154K$121K$172K
Total operating expenses$2.11M$2.72M$2.82M$2.99M$2.4M$2.39M$2.39M$2.46M
Operating income$2.65M$2.57M$2.44M$2.61M$3.2M$3.15M$2.93M$3.34M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$3.29M$3.18M$3.11M$3.31M$3.84M$3.86M$3.61M$4.18M
Income taxes$600K$578K$540K$678K$788K$817K$712K$616K
Net income$2.69M$2.6M$2.57M$2.63M$3.05M$3.04M$2.9M$3.56M
Net income attributable to common shareholders$2.69M$2.6M$2.57M$2.63M$3.05M$3.04M$2.9M$3.56M
EBITDA$2.88M$3.24M$3.19M$3.37M$3.94M$3.86M$3.65M$4.07M
Basic earnings per share$0.84$0.82$0.80$0.82$0.94$0.92$0.86$1.02
Diluted earnings per share$0.84$0.82$0.80$0.82$0.94$0.92$0.86$1.02

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

UTMD's Q3 Earnings Rise Y/Y on Lower Costs, Orion Acquisition

Utah Medical Products (UTMD) reported Q3 2026 earnings per share of 87.6 cents, up 6.8% year-over-year, but revenues declined 12.1% to $8.6 million due to lost customer sales and weaker demand for the Filshie Clip System. Despite lower sales, operating income increased 7% as the company reduced operating expenses and benefited from a lower tax rate. Management expects full-year 2026 revenues to decline approximately 7%, though uncertainty remains around new biopharmaceutical customer growth.

Zacks Investment Research

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.

Zacks Investment Research

Zacks Initiates Coverage of UTMD With Neutral Recommendation

Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.

Zacks Investment Research

Top Stock Reports for Apple, Mastercard & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.315 per share
Declared
Nov 3, 2026
Ex-dividend
Dec 17, 2026
Pay date
Jan 5, 2027
Ex-dividendAmount / sharePay dateType
Sep 17, 2026$0.31Oct 5, 2026recurring
Jun 17, 2026$0.31Jul 3, 2026recurring
Mar 17, 2026$0.31Apr 3, 2026recurring
Dec 16, 2025$0.31Jan 5, 2026recurring
Sep 17, 2025$0.305Oct 2, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.